7 results
Aim. The general aim of the study is to determine if cosmetic outcome will improve by applying silicone bandages to the wound. Cosmetic outcome is analyzed by size, colour, and surface of the scar. In addition it will be evaluated whether the…
This study will evaluate the efficacy and safety of ocrelizumab (Ocrevus®) compared with placebo in patients with PPMS, including patients later in their disease course.
The objective of this prospective, randomized study is to investigate the efficacy and safety of HSCT compared to the comparator group (alemtuzumab, cladribine or ocrelizumab) in patients with aggressive relapsing remitting MS. In Norway, the…
With this study we aim to prove that personalized B cell tailored ocrelizumab treatment is non-inferior in the suppression of MS disease activity (clinically and radiologically) compared to the standard (fixed 24 week interval) treatment.
Primary:To investigate the efficacy of ocrelizumab compared with placebo in patients with primary progressive multiple sclerosis, as measured by thetime to onset of confirmed disability progression over the treatment period, defined as an increase…
The main objective of this study is to assess the safety of combining Nivolumab with IRE alone and of combining Nivolumab with IRE and CpG .The secondary objectives of this study are : 1) whether the combination of Nivolumab + IRE, or of CpG +…
This study will evaluate the efficacy, safety, and pharmacokinetics of a higher dose of ocrelizumab compared with the approved dose of ocrelizumab in patients with relapsing forms of multiple sclerosis.